India to Kenya: Bevacizumab Export Trade Route
India has recorded 184 verified shipments of Bevacizumab exported to Kenya, representing a combined trade value of $930.4K USD. This corridor is served by 27 active Indian exporters, with an average shipment value of $5.1K USD. The leading Indian exporter is DR.REDDY'S LABORATORIES LTD, which accounts for 36% of total export value with 2 shipments worth $338.0K USD. On the buying side, NA is the largest importer in Kenya with $351.8K USD in purchases. The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, R.S. SURGIPHARM PRIVATE LIMITED, MYLAN PHARMACEUTICALS PRIVATE LIMITED — together control 60% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Kenya Bevacizumab corridor is one of India's established pharmaceutical export routes, with 184 shipments documented worth a combined $930.4K USD. The route is dominated by DR.REDDY'S LABORATORIES LTD, which alone accounts for roughly 36% of all export value, reflecting the consolidated nature of India's bevacizumab manufacturing sector.
Across 27 active suppliers, the average shipment value stands at $5.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 72% of all shipments, consistent with bevacizumab's non-urgent bulk-order profile.
Shipment activity peaks during July–September, with an average transit time of 33 days port-to-port. The route has recorded an annual growth rate of 29.6%, placing it at rank #7 among India's top bevacizumab export destinations globally.
On the import side, key buyers of Indian bevacizumab in Kenya include NA, TO, M/S. SURGILINKS LIMITED., and 32 others. NA is the single largest importer with 10 shipments valued at $351.8K USD.
Route Characteristics
- Average transit33 days
- Peak seasonQ3
- Primary modeSea freight
- Top portSAHAR AIR CARGO ACC (INBOM4)
Market Position
- Global rank#7
- Annual growth+29.6%
- Demand growth+26.6%
- Regulatory ease73/100
Top 10 Indian Bevacizumab Exporters to Kenya
Showing top 10 of 27 Indian suppliers exporting Bevacizumab to Kenya, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD Avg $169.0K per shipment | 2 | $338.0K | 36.3% |
| 2 | R.S. SURGIPHARM PRIVATE LIMITED Avg $3.0K per shipment | 40 | $119.8K | 12.9% |
| 3 | MYLAN PHARMACEUTICALS PRIVATE LIMITED Avg $50.3K per shipment | 2 | $100.6K | 10.8% |
| 4 | R.S. SURGIPHARM PRIVATE LIMITED Avg $3.3K per shipment | 28 | $92.9K | 10.0% |
| 5 | R S SURGIPHARM PRIVATE LIMITED Avg $2.7K per shipment | 22 | $58.3K | 6.3% |
| 6 | ASPIRA BIOHEALTH LLP Avg $2.5K per shipment | 11 | $28.0K | 3.0% |
| 7 | ASPIDA LIFE SCIENCES PRIVATE LIMITED Avg $2.5K per shipment | 10 | $24.6K | 2.6% |
| 8 | ZYDUS LIFESCIENCES LIMITED Avg $11.8K per shipment | 2 | $23.6K | 2.5% |
| 9 | SPECIALITY MEDICINES PRIVATE LIMITED Avg $3.6K per shipment | 6 | $21.8K | 2.3% |
| 10 | VAMA LIFECARE PRIVATE LIMITED Avg $4.2K per shipment | 5 | $20.8K | 2.2% |
This table shows the top 10 of 27 Indian companies exporting bevacizumab to Kenya, ranked by total trade value. The listed exporters are: DR.REDDY'S LABORATORIES LTD, R.S. SURGIPHARM PRIVATE LIMITED, MYLAN PHARMACEUTICALS PRIVATE LIMITED , R.S. SURGIPHARM PRIVATE LIMITED , R S SURGIPHARM PRIVATE LIMITED, ASPIRA BIOHEALTH LLP, ASPIDA LIFE SCIENCES PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED, SPECIALITY MEDICINES PRIVATE LIMITED, VAMA LIFECARE PRIVATE LIMITED. DR.REDDY'S LABORATORIES LTD is the dominant supplier with 2 shipments worth $338.0K USD, giving it a 36% market share. The top 3 suppliers together account for 60% of the total trade value on this route.
Showing top 10 of 27 total Indian exporters on the India to Kenya Bevacizumab export route.
Top 10 Bevacizumab Importers in Kenya
Showing top 10 of 35 known buyers in Kenya receiving Bevacizumab shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian bevacizumab in Kenya include NA, TO, M/S. SURGILINKS LIMITED., , TO , TO THE ORDER, among 35 total buyers. The largest importer is NA, accounting for $351.8K USD across 10 shipments — representing 38% of all bevacizumab imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | NA | 10 | $351.8K | 37.8% |
| 2 | TO | 49 | $141.8K | 15.2% |
| 3 | M/S. SURGILINKS LIMITED., | 2 | $100.6K | 10.8% |
| 4 | TO | 28 | $92.9K | 10.0% |
| 5 | TO THE ORDER | 7 | $26.6K | 2.9% |
| 6 | To The Order | 6 | $21.8K | 2.3% |
| 7 | AS PER INVOICE | 4 | $17.1K | 1.8% |
| 8 | TO THE ORDER OF INVOICE RAISED TO: | 6 | $16.6K | 1.8% |
| 9 | TO THE ORDER OF INVOICE RAISED TO | 9 | $16.2K | 1.7% |
| 10 | FOR THE ORDER OF | 8 | $15.6K | 1.7% |
Showing top 10 of 35 Bevacizumab importers in Kenya on this route.
Top 10 Bevacizumab Formulations Imported by Kenya
Showing top 10 of 113 product formulations shipped on the India to Kenya Bevacizumab route, ranked by trade value
Kenya imports a wide range of bevacizumab formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — BEVACIZUMAB SOLUTION FOR INFUSION 400MG(PERSIVIA 400)(QTY:1700 VIALS) — accounts for $301.1K USD across 1 shipments. There are 113 distinct product descriptions in the dataset, reflecting the variety of dosage forms and strengths imported.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | BEVACIZUMAB SOLUTION FOR INFUSION 400MG(PERSIVIA 400)(QTY:1700 VIALS) | 1 | $301.1K | 32.4% |
| 2 | BEVACIZUMAB 400MG INJ (1 VIAL) | 21 | $100.5K | 10.8% |
| 3 | BEVACIZUMAB CSI 400MG/16ML 1 VL IN MY | 1 | $67.6K | 7.3% |
| 4 | BEVACIZUMAB SOLUTION FOR INFUSION 100MG(PERSIVIA 100)(QTY:750 VIALS) | 1 | $36.9K | 4.0% |
| 5 | BEVACIZUMAB CSI 100MG/4ML 1 VL IN MY | 1 | $33.0K | 3.6% |
| 6 | REWARD ITEM HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE BEVACIZUMAB 400MGFOR INJECTION CIZUMAB 400MG | 3 | $21.0K | 2.3% |
| 7 | (HARMLESS MEDICINES FOR INJECTABLEAND CAPSULES AND TABLETS) BEVACIZUMAB INJECTION 400MG (UNIT PACK : 1 VIAL) | 1 | $14.7K | 1.6% |
| 8 | HARMLESS MEDICINES INJECATABLE AND TABLETS BEVACIZUMAB 400MG INJECTION 1 VIAL | 2 | $14.6K | 1.6% |
| 9 | BRYXTA 400MG (BEVACIZUMAB 400MG/ 16ML) ( | 1 | $14.1K | 1.5% |
| 10 | BEVACIZUMAB CONCENTRATE SOLUTION FOR INFUSION 400 MG / 16 ML IN SINGLE USE VIAL1*1 VIAL BATCH NO .: 24030104 | 2 | $12.5K | 1.3% |
Showing top 10 of 113 Bevacizumab formulations imported by Kenya on this route.
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 72%, typical for bulk pharmaceutical shipments.
Top Ports of Origin
SAHAR AIR CARGO ACC (INBOM4) handles the highest volume with 72 shipments. Transit time averages 33 days by sea.
Market Dynamics
India's bevacizumab exports to Kenya are driven primarily by a handful of large-scale manufacturers. DR.REDDY'S LABORATORIES LTD with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 27 active exporters signals a competitive but concentrated market — buyers in Kenya benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, R.S. SURGIPHARM PRIVATE LIMITED, MYLAN PHARMACEUTICALS PRIVATE LIMITED — together account for 60% of total trade value on this route. The average shipment value of $5.1K USD reflects a mix of bulk commercial orders and smaller specialty shipments.
Beyond the primary product category, shipments on this route include closely related formulations such as bevacizumab 400mg inj (1 vial) and bevacizumab csi 400mg/16ml 1 vl in my , suggesting that buyers in Kenya tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, NA is the largest importer with 10 shipments worth $351.8K USD — representing 38% of all bevacizumab imports from India on this route. A total of 35 buyers are active on this corridor.
Route Statistics
- Trade Volume
- $930.4K
- Avg. Shipment
- $5.1K
- Suppliers
- 27
- Buyers
- 35
- Transit (Sea)
- ~33 days
- Annual Growth
- +29.6%
Related Analysis
Other Bevacizumab Routes
Unlock the Full India to Kenya Bevacizumab Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 184 shipments on this route.
Frequently Asked Questions — India to Kenya Bevacizumab Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Bevacizumab to Kenya?
The leading Indian exporters of Bevacizumab to Kenya are DR.REDDY'S LABORATORIES LTD, R.S. SURGIPHARM PRIVATE LIMITED, MYLAN PHARMACEUTICALS PRIVATE LIMITED . DR.REDDY'S LABORATORIES LTD holds the largest market share at approximately 36% of total trade value on this route.
Q What is the total value of Bevacizumab exports from India to Kenya?
India exports Bevacizumab to Kenya worth approximately $930.4K USD across 184 recorded shipments. The average value per shipment is $5.1K USD.
Q Which ports does India use to ship Bevacizumab to Kenya?
The most active port of origin is SAHAR AIR CARGO ACC (INBOM4) with 72 shipments. Indian exporters primarily use sea freight for this route, with 72% of shipments going by sea and 20% by air.
Q How long does shipping take from India to Kenya for Bevacizumab?
The average transit time for Bevacizumab shipments from India to Kenya is approximately 33 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during July–September.
Q Is the India to Kenya Bevacizumab trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 29.6% with demand growth tracking at 26.6%. The route is ranked #7 among India's top Bevacizumab export destinations globally.
Q How many suppliers are active on the India to Kenya Bevacizumab route?
There are currently 27 active Indian suppliers exporting Bevacizumab to Kenya. The market is moderately concentrated with DR.REDDY'S LABORATORIES LTD accounting for 36% of total shipment value.
Q Who are the main importers of Bevacizumab from India in Kenya?
The leading importers of Indian Bevacizumab in Kenya include NA, TO, M/S. SURGILINKS LIMITED., , TO , TO THE ORDER. NA is the largest buyer with 10 shipments worth $351.8K USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to Kenya export trade corridor identified from Indian Customs (DGFT) records for Bevacizumab.
- 2.Supplier/Buyer Matching: 27 Indian exporters and 35 importers in Kenya matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 184 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
184 Verified Shipments
27 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists